利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

116 条记录 (耗时 0.015 秒)

    SOLID DOSAGE FORMULATIONS OF HYDRALAZINE COMPOUNDS
    3.
    发明公开
    SOLID DOSAGE FORMULATIONS OF HYDRALAZINE COMPOUNDS 审中-公开
    肼类化合物的固体剂量配方

    公开(公告)号：EP2024337A1

    公开(公告)日：2009-02-18

    申请号：EP07777070.9

    申请日：2007-05-16

    申请人： Nitromed, Inc.

    发明人： LETTS, L., Gordon

    IPC分类号： C07D237/26 ,  A01N25/34

    CPC分类号： A61K9/2054 ,  A61K9/2059 ,  A61K31/34 ,  A61K31/502 ,  A61K45/06 ,  Y02A50/411 ,  A61K2300/00

    摘要： The invention provides solid dosage formulations, methods of making and using the formulations comprising at least one hydralazine compound or a pharmaceutically acceptable salt thereof, and at least one excipient or carrier, wherein the formulations have less than about 0.001% to about 0.1% of a hydrazone compound based on the total weight of the formulation. The invention also provides solid dosage formulations, methods of making and using the formulations comprising at least one hydralazine compound or a pharmaceutically acceptable salt thereof, and at least one nitric oxide donor compound or a pharmaceutically acceptable salt thereof and at least one excipient or carrier, wherein the formulations have less than about 0.001% to about 0.1% of a hydrazone compound based on the total weight of the formulation.

    摘要翻译： 本发明提供了固体剂型，制备和使用包含至少一种肼屈嗪化合物或其药学上可接受的盐和至少一种赋形剂或载体的制剂的方法，其中所述制剂具有小于约0.001％至约0.1％的 腙化合物，基于配方的总重量。 本发明还提供固体剂量制剂，制备和使用包含至少一种肼屈嗪化合物或其药学上可接受的盐和至少一种一氧化氮供体化合物或其药学上可接受的盐以及至少一种赋形剂或载体的制剂的方法， 其中所述制剂具有基于所述制剂的总重量小于约0.001％至约0.1％的腙化合物。

    NITRIC OXIDE ENHANCING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE
    4.
    发明公开
    NITRIC OXIDE ENHANCING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE 审中-公开
    氮氧化物补强PYRUVATE化合物，组合物及使用方法

    公开(公告)号：EP1971340A2

    公开(公告)日：2008-09-24

    申请号：EP06845699.5

    申请日：2006-12-19

    申请人： Nitromed, Inc.

    发明人： GARVEY, David, S.

    IPC分类号： A61K31/537 ,  A61K31/421

    CPC分类号： A61K31/421 ,  A61K31/537

    摘要： The invention provides novel compositions and kits comprising at least one nitric oxide enhancing pyruvate compound, or a pharmaceutically acceptable salt thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; (j) treating osteoporosis; (k) treating nephropathy; (1) treating peripheral vascular diseases; (m) treating portal hypertension; (n) treating reperfusion injury following ischemia; and/or (m) preserving tissues, organs, organ parts and/or limbs. The nitric oxide enhancing pyruvate compounds comprise at least one heterocyclic nitric oxide donor group and/or at least one nitroxide group.

    NITRIC OXIDE ENHANCING GLUTAMIC ACID COMPOUNDS, COMPOSITIONS AND METHODS OF USE
    5.
    发明公开
    NITRIC OXIDE ENHANCING GLUTAMIC ACID COMPOUNDS, COMPOSITIONS AND METHODS OF USE 审中-公开
    氮氧化物增强谷氨酸化合物，组合物及使用方法

    公开(公告)号：EP1968584A2

    公开(公告)日：2008-09-17

    申请号：EP06845698.7

    申请日：2006-12-19

    申请人： Nitromed, Inc.

    发明人： GARVEY, David, S.

    IPC分类号： A61K31/4245

    CPC分类号： A61K31/4245

    摘要： The invention provides novel compositions and kits comprising at least one nitric oxide enhancing glutamic acid compound, or a pharmaceutically acceptable salt thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; (j) treating osteoporosis; (k) treating nephropathy; (1) treating peripheral vascular diseases; (m) treating portal hypertension; (n) treating diseases resulting from elevated levels of gamma-glutamyl transpeptidase and (o) targeting the delivery of compounds and nitric oxide to organs, cells or tissues that contain the enzyme gamma-glutamyl transpeptidase. The nitric oxide enhancing glutamic acid compounds comprise at least one heterocyclic nitric oxide donor group and/or at least one nitroxide group.

    THE GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF GENETIC VARIATION OF ALDOSTERONE SYNTHASE PROMOTER POLYMORPHISM
    6.
    发明公开
    THE GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF GENETIC VARIATION OF ALDOSTERONE SYNTHASE PROMOTER POLYMORPHISM 审中-公开
    遗传风险评估心力衰竭：影响醛固酮合成酶基因多态性的遗传变异的

    公开(公告)号：EP1943361A2

    公开(公告)日：2008-07-16

    申请号：EP06825494.5

    申请日：2006-10-04

    申请人： Nitromed, Inc. ,  University of Pittsburgh of the Commonwealth System of Higher Education

    发明人： WORCEL, Manuel ,  SABOLINSKI, Michael, L. ,  TAM, Sang, William ,  McNAMARA, Dennis, M.

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/156 ,  C12Q2600/172

    摘要： The invention provides methods for (a) reducing mortality associated with heart failure; (b) improving oxygen consumption; (c) treating heart failure; (d) treating hypertension; (e) improving the quality of life in a heart failure patient; (f) inhibiting left ventricular remodeling; (g) reducing hospitalizations related to heart failure; (h) improving exercise tolerance; (j) increasing left ventricular ejection fraction; (Ic) decreasing levels of B-type natriuretic protein; (1) treating renovascular diseases; (m) treating end-stage renal diseases; (n) reducing cardiomegaly; (o) treating diseases resulting from oxidative stress; (p) treating endothelial dysfunctions; (q) treating diseases caused by endothelial dysfunctions; or (r) treating cardiovascular diseases; in a patient in need thereof, wherein the patient has a -344 (T/T) polymorphism or a -344 (C/C) polymorphism in an aldosterone synthase CYPl1B2 gene, comprising administering to the patient (i) at least one antioxidant compound or a pharmaceutically acceptable salt thereof; (ii) at least one nitric oxide enhancing compound; and (iii) optionally the best current therapy for the treatment of cardiovascular diseases. In one embodiment the antioxidant is a hydralazine compound or a pharmaceutically acceptable salt thereof and the nitric oxide enhancing compound is isosorbide dinitrate and/or isosorbide mononitrate.

    ORGANIC NITRIC OXIDE ENHANCING SALTS OF NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE
    8.
    发明公开
    ORGANIC NITRIC OXIDE ENHANCING SALTS OF NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE 审中-公开
    有机氮氧化物增强从非甾体抗炎化合物和组合物及其使用方法盐类

    公开(公告)号：EP1883614A2

    公开(公告)日：2008-02-06

    申请号：EP06770830.5

    申请日：2006-05-23

    申请人： Nitromed, Inc.

    发明人： GARVEY, David, S.

    IPC分类号： C07C7/10 ,  B32B15/00 ,  A61K31/60

    CPC分类号： C07C229/42 ,  C07C57/58 ,  C07C59/64 ,  C07C59/68 ,  C07C59/84 ,  C07C59/86 ,  C07C59/88 ,  C07C313/36 ,  C07D209/12 ,  C07D263/32 ,  C07D277/24 ,  C07D279/12 ,  C07D333/22 ,  C07D471/04 ,  C07D498/04

    摘要： The invention describes novel organic nitric oxide enhancing salts of nonsteroidal antiinflammatory drugs (NSAIDs) and novel compositions comprising at least one organic nitric oxide enhancing salt of an NSAID, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides novel compositions and kits comprising at least one organic nitric oxide enhancing salt of an NSAID, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating inflammation, pain and fever; (b) treating gastrointestinal disorders; (c) facilitating wound healing; (d) treating gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; (e) treating inflammatory disease states and/or disorders; (f) treating ophthalmic disorders; (h) treating peripheral vascular diseases; (i) treating diseases resulting from oxidative stress; (j) treating endothelial dysfunctions; and (k) treating diseases caused by endothelial dysfunctions. The organic nitric oxide enhancing compounds that form salts with the NSAIDs are organic nitrates, organic nitrites, nitrosothiols, thionitrites, thionitrates, NONOates, heterocyclic nitric oxide donors and/or nitroxides. The heterocyclic nitric oxide donors are furoxans, sydnonimines, oxatriazole-5-ones and/or oxatriazole-5- imines.